• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ALCON RESEARCH, LLC - HUNTINGTON ACRYSOF IQ NATURAL SINGLEPIECE IOL; INTRAOCULAR LENS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ALCON RESEARCH, LLC - HUNTINGTON ACRYSOF IQ NATURAL SINGLEPIECE IOL; INTRAOCULAR LENS Back to Search Results
Model Number SN60WF
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Inflammation (1932); Pain (1994); Visual Impairment (2138); Toxicity (2333)
Event Date 10/21/2019
Event Type  Injury  
Manufacturer Narrative
The product was not returned for analysis.The product history and batch records were reviewed and documentation indicated the product met release criteria.The product investigation could not identify a root cause.There have been no other complaints reported in the lot number.The manufacturer internal reference number is: (b)(4).
 
Event Description
A physician reported that following an intraocular lens (iol) implant procedure, a patient developed toxic anterior segment syndrome (tass).On the 5th postoperative day, the patient had pain.The following day, the patient had 1-2+ cell, not too bad.The physician switched out one steroid eye medication for another and added an antibiotic fluoroquinolone medication.The patient did not show up for the follow up appointment.The daily attempts made to get her in were not successful.On the 12th postoperative day, the patient called the physician to report worsening pain and "dark" vision.The patient did not come in again.Additional information was provided indicating that the patient developed 1+ conjunctival inflammation, 1+ aqueous cell.The patient had postop pain, 1-2+ cell, decreased vision and photophobia.Slightly elevated inflammation on the 5th postoperative day without concern of endophthalmitis.It is unknown if the topical medication adjustment was effective as the patient has failed to show for daily checks for over 1 week.The outcome of the event is unknown.Other potentially contributing factors were reported as diabetes.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ACRYSOF IQ NATURAL SINGLEPIECE IOL
Type of Device
INTRAOCULAR LENS
Manufacturer (Section D)
ALCON RESEARCH, LLC - HUNTINGTON
6065 kyle lane
huntington WV 25702
Manufacturer (Section G)
ALCON RESEARCH, LLC - HUNTINGTON
6065 kyle lane
huntington WV 25702
Manufacturer Contact
cindy milam
6201 south freeway
mail stop ab2-6
fort worth, TX 76134
8176152231
MDR Report Key9347680
MDR Text Key167194571
Report Number1119421-2019-01942
Device Sequence Number1
Product Code HQL
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P930014
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional
Reporter Occupation Physician
Type of Report Initial
Report Date 11/20/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/20/2019
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberSN60WF
Device Catalogue NumberSN60WF.190
Device Lot Number12719156
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received10/28/2019
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured06/19/2019
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
BESIVANCE 4X; BSS 15ML-USA, 0065079515, 0007950004, FTW - NORTH; DUREZOL 6X; ILEVRO; LOTEMAX; UNSPECIFIED CUSTOM PAK, HTX; UNSPECIFIED HANDPIECE, UNKNOWN SYSTEM, ITC; UNSPECIFIED PROVISC OVD, 000451, BEL; UNSPECIFIED VISCOAT OVD, 000452, BEL
Patient Outcome(s) Required Intervention;
Patient Age60 YR
-
-